Watch the Dallas Symposium LIVE, and fundraiser auction
Ticket proceeds support mindat.org! - click here...
Log InRegister
Quick Links : The Mindat ManualThe Rock H. Currier Digital LibraryMindat Newsletter [Free Download]
Home PageAbout MindatThe Mindat ManualHistory of MindatCopyright StatusWho We AreContact UsAdvertise on Mindat
Donate to MindatCorporate SponsorshipSponsor a PageSponsored PagesMindat AdvertisersAdvertise on Mindat
Learning CenterWhat is a mineral?The most common minerals on earthInformation for EducatorsMindat ArticlesThe ElementsThe Rock H. Currier Digital LibraryGeologic Time
Minerals by PropertiesMinerals by ChemistryAdvanced Locality SearchRandom MineralRandom LocalitySearch by minIDLocalities Near MeSearch ArticlesSearch GlossaryMore Search Options
Search For:
Mineral Name:
Locality Name:
Keyword(s):
 
The Mindat ManualAdd a New PhotoRate PhotosLocality Edit ReportCoordinate Completion ReportAdd Glossary Item
Mining CompaniesStatisticsUsersMineral MuseumsClubs & OrganizationsMineral Shows & EventsThe Mindat DirectoryDevice SettingsThe Mineral Quiz
Photo SearchPhoto GalleriesSearch by ColorNew Photos TodayNew Photos YesterdayMembers' Photo GalleriesPast Photo of the Day GalleryPhotography

(2020, July) Reactions Weekly Vol. 1814 (1) Springer Science and Business Media LLC

Advanced
   -   Only viewable:
Reference TypeJournal (issue)
JournalReactions Weekly
Year2020 (July)Volume1814
Issue1
PublisherSpringer Science and Business Media LLC
Mindat Ref. ID13404865Long-form Identifiermindat:1:5:13404865:1
GUID0
Full Reference(2020, July) Reactions Weekly Vol. 1814 (1) Springer Science and Business Media LLC
Plain Text(2020, July) Reactions Weekly Vol. 1814 (1) Springer Science and Business Media LLC
In(2020) Reactions Weekly Vol. 1814. Springer Science and Business Media LLC

Contains

1 2
Page 1 of 2		Next Page
(2020) Clobazam oral suspensions shown not to be bioequivalent to tablets. Reactions Weekly, 1814 (1) 1 doi:10.1007/s40278-020-80988-8
(2020) EMA's CHMP issues opinion on nitrosamine impurities in medicines. Reactions Weekly, 1814 (1) 2 doi:10.1007/s40278-020-80989-8
(2020) FDA adds warning to baricitinib label: hypersensitivity. Reactions Weekly, 1814 (1) 3 doi:10.1007/s40278-020-80990-7
(2020) AE costs lower with liso-cel than with axi-cel or tisagenlecleucel. Reactions Weekly, 1814 (1) 4 doi:10.1007/s40278-020-80991-7
(2020) Azithromycin prolongs QT interval in paediatric patients. Reactions Weekly, 1814 (1) 5 doi:10.1007/s40278-020-80992-7
(2020) Cardiovascular adverse events: abaloparatide vs teriparatide, placebo. Reactions Weekly, 1814 (1) 6 doi:10.1007/s40278-020-80993-7
(2020) Changes in diclofenac initiation after label changes due to safety. Reactions Weekly, 1814 (1) 7 doi:10.1007/s40278-020-80994-7
(2020) Hospital antibiotic use in patients with documented penicillin allergy. Reactions Weekly, 1814 (1) 8 doi:10.1007/s40278-020-80995-7
(2020) Risk of bradycardia with lopinavir/ritonavir in COVID-19 patients. Reactions Weekly, 1814 (1) 9 doi:10.1007/s40278-020-80996-7
(2020) Risk of GI bleeding lower with prasugrel or ticagrelor than clopidogrel. Reactions Weekly, 1814 (1) 10 doi:10.1007/s40278-020-80997-7
(2020) Serious idiosyncratic liver injury with ulipristal acetate. Reactions Weekly, 1814 (1) 11 doi:10.1007/s40278-020-80998-7
(2020) Vedolizumab vs TNF antagonists in patients with Crohn's disease. Reactions Weekly, 1814 (1) 12 doi:10.1007/s40278-020-80999-7
(2020) Other adverse reaction research. Reactions Weekly, 1814 (1) 13 doi:10.1007/s40278-020-81000-5
(2020) β-adrenergic receptor antagonists/Digoxin. Reactions Weekly, 1814 (1) 14 doi:10.1007/s40278-020-81001-5
(2020) Acetate/bicarbonate/calcium/chloride/glucose/magnesium/potassium/sodium. Reactions Weekly, 1814 (1) 15 doi:10.1007/s40278-020-81002-5
(2020) Adalimumab/certolizumab-pegol. Reactions Weekly, 1814 (1) 16 doi:10.1007/s40278-020-81003-5
(2020) Adefovir-dipivoxil/lamivudine. Reactions Weekly, 1814 (1) 17 doi:10.1007/s40278-020-81004-5
(2020) Albumin human/dopamine. Reactions Weekly, 1814 (1) 18 doi:10.1007/s40278-020-81005-5
(2020) Alectinib/lorlatinib. Reactions Weekly, 1814 (1) 19 doi:10.1007/s40278-020-81006-5
(2020) Alemtuzumab. Reactions Weekly, 1814 (1) 20 doi:10.1007/s40278-020-81007-5
(2020) Alemtuzumab. Reactions Weekly, 1814 (1) 21 doi:10.1007/s40278-020-81008-5
(2020) Alemtuzumab. Reactions Weekly, 1814 (1) 22 doi:10.1007/s40278-020-81009-5
(2020) Alemtuzumab/methylprednisolone. Reactions Weekly, 1814 (1) 23 doi:10.1007/s40278-020-81010-4
(2020) Alendronic acid. Reactions Weekly, 1814 (1) 24 doi:10.1007/s40278-020-81011-4
(2020) Alfacalcidol/calcium carbonate. Reactions Weekly, 1814 (1) 25 doi:10.1007/s40278-020-81012-4
(2020) Allopurinol. Reactions Weekly, 1814 (1) 26 doi:10.1007/s40278-020-81013-4
(2020) Allopurinol/azathioprine interaction. Reactions Weekly, 1814 (1) 27 doi:10.1007/s40278-020-81014-4
(2020) Allopurinol/dasatinib/ponatinib. Reactions Weekly, 1814 (1) 28 doi:10.1007/s40278-020-81015-4
(2020) Alprazolam overdose. Reactions Weekly, 1814 (1) 29 doi:10.1007/s40278-020-81016-4
(2020) Alprostadil. Reactions Weekly, 1814 (1) 30 doi:10.1007/s40278-020-81017-4
(2020) Alteplase. Reactions Weekly, 1814 (1) 31 doi:10.1007/s40278-020-81018-4
(2020) Ambrisentan/tadalafil. Reactions Weekly, 1814 (1) 32 doi:10.1007/s40278-020-81019-4
(2020) Amiodarone/methylprednisolone/prednisolone. Reactions Weekly, 1814 (1) 33 doi:10.1007/s40278-020-81020-3
(2020) Amitriptyline. Reactions Weekly, 1814 (1) 34 doi:10.1007/s40278-020-81021-3
(2020) Amphotericin B liposomal/voriconazole. Reactions Weekly, 1814 (1) 35 doi:10.1007/s40278-020-81022-3
(2020) Amphotericin B/dexamethasone/fluconazole. Reactions Weekly, 1814 (1) 36 doi:10.1007/s40278-020-81023-3
(2020) Amphotericin-B-liposomal/immunosuppressants interaction. Reactions Weekly, 1814 (1) 37 doi:10.1007/s40278-020-81024-3
(2020) Ampicillin/gentamicin. Reactions Weekly, 1814 (1) 38 doi:10.1007/s40278-020-81025-3
(2020) Ampicillin/levothyroxine-sodium. Reactions Weekly, 1814 (1) 39 doi:10.1007/s40278-020-81026-3
(2020) Ampicillin/sulbactam/meropenem. Reactions Weekly, 1814 (1) 40 doi:10.1007/s40278-020-81027-3
(2020) Anaesthetics. Reactions Weekly, 1814 (1) 41 doi:10.1007/s40278-020-81028-3
(2020) Anakinra/canakinumab/colchicine. Reactions Weekly, 1814 (1) 42 doi:10.1007/s40278-020-81029-3
(2020) Anakinra/colchicine. Reactions Weekly, 1814 (1) 43 doi:10.1007/s40278-020-81030-2
(2020) Anidulafungin/dexamethasone. Reactions Weekly, 1814 (1) 44 doi:10.1007/s40278-020-81031-2
(2020) Anti-bacterials/hydroxychloroquine/voriconazole. Reactions Weekly, 1814 (1) 45 doi:10.1007/s40278-020-81032-2
(2020) Antiasthmatics. Reactions Weekly, 1814 (1) 46 doi:10.1007/s40278-020-81033-2
(2020) Antibacterials/dopamine/norepinephrine. Reactions Weekly, 1814 (1) 47 doi:10.1007/s40278-020-81034-2
(2020) Antibacterials/immunosuppressants. Reactions Weekly, 1814 (1) 48 doi:10.1007/s40278-020-81035-2
(2020) Antibiotics. Reactions Weekly, 1814 (1) 49 doi:10.1007/s40278-020-81036-2
(2020) Antibiotics/isoflurane. Reactions Weekly, 1814 (1) 50 doi:10.1007/s40278-020-81037-2
(2020) Anticoagulant/aspirin. Reactions Weekly, 1814 (1) 51 doi:10.1007/s40278-020-81038-2
(2020) Antidepressants/valproic-acid. Reactions Weekly, 1814 (1) 52 doi:10.1007/s40278-020-81039-2
(2020) Antiepileptic drugs. Reactions Weekly, 1814 (1) 53 doi:10.1007/s40278-020-81040-1
(2020) Antiepileptic drugs/immunotherapies. Reactions Weekly, 1814 (1) 54 doi:10.1007/s40278-020-81041-1
(2020) Antihyperglycaemics/ibuprofen. Reactions Weekly, 1814 (1) 55 doi:10.1007/s40278-020-81042-1
(2020) Antineoplastics. Reactions Weekly, 1814 (1) 56 doi:10.1007/s40278-020-81043-1
(2020) Antineoplastics. Reactions Weekly, 1814 (1) 57 doi:10.1007/s40278-020-81044-1
(2020) Antineoplastics. Reactions Weekly, 1814 (1) 58 doi:10.1007/s40278-020-81045-1
(2020) Antineoplastics. Reactions Weekly, 1814 (1) 59 doi:10.1007/s40278-020-81046-1
(2020) Antineoplastics. Reactions Weekly, 1814 (1) 60 doi:10.1007/s40278-020-81047-1
(2020) Antineoplastics. Reactions Weekly, 1814 (1) 61 doi:10.1007/s40278-020-81048-1
(2020) Antineoplastics. Reactions Weekly, 1814 (1) 62 doi:10.1007/s40278-020-81049-1
(2020) Antineoplastics. Reactions Weekly, 1814 (1) 63 doi:10.1007/s40278-020-81050-0
(2020) Antineoplastics. Reactions Weekly, 1814 (1) 64 doi:10.1007/s40278-020-81051-0
(2020) Antineoplastics. Reactions Weekly, 1814 (1) 65 doi:10.1007/s40278-020-81052-0
(2020) Antineoplastics. Reactions Weekly, 1814 (1) 66 doi:10.1007/s40278-020-81053-0
(2020) Antineoplastics. Reactions Weekly, 1814 (1) 67 doi:10.1007/s40278-020-81054-0
(2020) Antineoplastics. Reactions Weekly, 1814 (1) 68 doi:10.1007/s40278-020-81055-0
(2020) Antineoplastics. Reactions Weekly, 1814 (1) 69 doi:10.1007/s40278-020-81056-0
(2020) Antineoplastics and immunosuppressants. Reactions Weekly, 1814 (1) 70 doi:10.1007/s40278-020-81057-0
(2020) Antineoplastics/folinic acid. Reactions Weekly, 1814 (1) 71 doi:10.1007/s40278-020-81058-0
(2020) Antineoplastics/folinic acid. Reactions Weekly, 1814 (1) 72 doi:10.1007/s40278-020-81059-0
(2020) Antineoplastics/folinic acid. Reactions Weekly, 1814 (1) 73 doi:10.1007/s40278-020-81060-z
(2020) Antineoplastics/immunosuppressants. Reactions Weekly, 1814 (1) 74 doi:10.1007/s40278-020-81061-z
(2020) Antipsychotics/valproate. Reactions Weekly, 1814 (1) 75 doi:10.1007/s40278-020-81062-z
(2020) Antithymocyte globulin. Reactions Weekly, 1814 (1) 76 doi:10.1007/s40278-020-81063-z
(2020) Antituberculars/dexamethasone/prednisone. Reactions Weekly, 1814 (1) 77 doi:10.1007/s40278-020-81064-z
(2020) Ascorbic acid. Reactions Weekly, 1814 (1) 78 doi:10.1007/s40278-020-81065-z
(2020) Aspirin/clopidogrel. Reactions Weekly, 1814 (1) 79 doi:10.1007/s40278-020-81066-z
(2020) Aspirin/iodixanol. Reactions Weekly, 1814 (1) 80 doi:10.1007/s40278-020-81067-z
(2020) Asunaprevir/daclatasvir. Reactions Weekly, 1814 (1) 81 doi:10.1007/s40278-020-81068-z
(2020) Atezolizumab/pembrolizumab. Reactions Weekly, 1814 (1) 82 doi:10.1007/s40278-020-81069-z
(2020) Atovaquone/azithromycin. Reactions Weekly, 1814 (1) 83 doi:10.1007/s40278-020-81070-y
(2020) Azathioprine/ciclosporin/prednisolone. Reactions Weekly, 1814 (1) 84 doi:10.1007/s40278-020-81071-y
(2020) Azathioprine/infliximab/steroids. Reactions Weekly, 1814 (1) 85 doi:10.1007/s40278-020-81072-y
(2020) Azithromycin/hydroxychloroquine. Reactions Weekly, 1814 (1) 86 doi:10.1007/s40278-020-81073-y
(2020) Bacampicillin. Reactions Weekly, 1814 (1) 87 doi:10.1007/s40278-020-81074-y
(2020) Benzylpenicillin/flucloxacillin. Reactions Weekly, 1814 (1) 88 doi:10.1007/s40278-020-81075-y
(2020) Benzylthiouracil. Reactions Weekly, 1814 (1) 89 doi:10.1007/s40278-020-81076-y
(2020) Bevacizumab. Reactions Weekly, 1814 (1) 90 doi:10.1007/s40278-020-81077-y
(2020) Bevacizumab. Reactions Weekly, 1814 (1) 91 doi:10.1007/s40278-020-81078-y
(2020) Bicarbonate/insulin/sodium-chloride. Reactions Weekly, 1814 (1) 92 doi:10.1007/s40278-020-81079-y
(2020) Bortezomib/cyclophosphamide/dexamethasone. Reactions Weekly, 1814 (1) 93 doi:10.1007/s40278-020-81080-x
(2020) Bromhexine/bromhexine/tetracycline. Reactions Weekly, 1814 (1) 94 doi:10.1007/s40278-020-81081-x
(2020) Budesonide/formoterol/methylprednisolone. Reactions Weekly, 1814 (1) 95 doi:10.1007/s40278-020-81082-x
(2020) Buformin overdose. Reactions Weekly, 1814 (1) 96 doi:10.1007/s40278-020-81083-x
(2020) Bupivacaine/chlorpromazine/lidocaine. Reactions Weekly, 1814 (1) 97 doi:10.1007/s40278-020-81084-x
(2020) Cabazitaxel. Reactions Weekly, 1814 (1) 98 doi:10.1007/s40278-020-81085-x
(2020) Capecitabine/oxaliplatin/pemetrexed. Reactions Weekly, 1814 (1) 99 doi:10.1007/s40278-020-81086-x
(2020) Carbamazepine. Reactions Weekly, 1814 (1) 100 doi:10.1007/s40278-020-81087-x
(2020) Carnitine/sodium bicarbonate. Reactions Weekly, 1814 (1) 101 doi:10.1007/s40278-020-81088-x
(2020) Cefalexin/cefixime/phenytoin. Reactions Weekly, 1814 (1) 102 doi:10.1007/s40278-020-81089-x
(2020) Cefepime/ceftriaxone. Reactions Weekly, 1814 (1) 103 doi:10.1007/s40278-020-81090-9
(2020) Cefepime/clindamycin/levofloxacin. Reactions Weekly, 1814 (1) 104 doi:10.1007/s40278-020-81091-9
(2020) Ceftriaxone. Reactions Weekly, 1814 (1) 105 doi:10.1007/s40278-020-81092-9
(2020) Ceftriaxone. Reactions Weekly, 1814 (1) 106 doi:10.1007/s40278-020-81093-9
(2020) Chloroquine. Reactions Weekly, 1814 (1) 107 doi:10.1007/s40278-020-81094-9
(2020) Chloroquine. Reactions Weekly, 1814 (1) 108 doi:10.1007/s40278-020-81095-9
(2020) Ciclosporin. Reactions Weekly, 1814 (1) 109 doi:10.1007/s40278-020-81096-9
(2020) Ciclosporin/methylprednisolone/prednisone. Reactions Weekly, 1814 (1) 110 doi:10.1007/s40278-020-81097-9
(2020) Ciclosporin/methylprednisolone/tocilizumab. Reactions Weekly, 1814 (1) 111 doi:10.1007/s40278-020-81098-9
(2020) Ciclosporin/prednisolone. Reactions Weekly, 1814 (1) 112 doi:10.1007/s40278-020-81099-9
(2020) Cisplatin/gemcitabine/pembrolizumab. Reactions Weekly, 1814 (1) 113 doi:10.1007/s40278-020-81100-3
(2020) Clindamycin. Reactions Weekly, 1814 (1) 114 doi:10.1007/s40278-020-81101-3
(2020) Clindamycin/tacrolimus. Reactions Weekly, 1814 (1) 115 doi:10.1007/s40278-020-81102-3
(2020) Clonidine. Reactions Weekly, 1814 (1) 116 doi:10.1007/s40278-020-81103-3
(2020) Clozapine. Reactions Weekly, 1814 (1) 117 doi:10.1007/s40278-020-81104-3
(2020) Clozapine withdrawal. Reactions Weekly, 1814 (1) 118 doi:10.1007/s40278-020-81105-3
(2020) Colchicine. Reactions Weekly, 1814 (1) 119 doi:10.1007/s40278-020-81106-3
(2020) Colchicine/heparin/prednisolone. Reactions Weekly, 1814 (1) 120 doi:10.1007/s40278-020-81107-3
(2020) Cotrimoxazole/etanercept. Reactions Weekly, 1814 (1) 121 doi:10.1007/s40278-020-81108-3
(2020) Cyclophosphamide. Reactions Weekly, 1814 (1) 122 doi:10.1007/s40278-020-81109-3
(2020) Cyclophosphamide/rituximab. Reactions Weekly, 1814 (1) 123 doi:10.1007/s40278-020-81110-2
(2020) Dabigatran etexilate. Reactions Weekly, 1814 (1) 124 doi:10.1007/s40278-020-81111-2
(2020) Dabrafenib/vemurafenib. Reactions Weekly, 1814 (1) 125 doi:10.1007/s40278-020-81112-2
(2020) Degarelix. Reactions Weekly, 1814 (1) 126 doi:10.1007/s40278-020-81113-2
(2020) Desoximetasone. Reactions Weekly, 1814 (1) 127 doi:10.1007/s40278-020-81114-2
(2020) Dexamethasone. Reactions Weekly, 1814 (1) 128 doi:10.1007/s40278-020-81115-2
(2020) Dexamethasone. Reactions Weekly, 1814 (1) 129 doi:10.1007/s40278-020-81116-2
(2020) Dexamethasone. Reactions Weekly, 1814 (1) 130 doi:10.1007/s40278-020-81117-2
(2020) Dexamethasone/prednisolone acetate/triamcinolone. Reactions Weekly, 1814 (1) 131 doi:10.1007/s40278-020-81118-2
(2020) Diclofenac. Reactions Weekly, 1814 (1) 132 doi:10.1007/s40278-020-81119-2
(2020) Dinutuximab/interleukin-2. Reactions Weekly, 1814 (1) 133 doi:10.1007/s40278-020-81120-1
(2020) Dobutamine. Reactions Weekly, 1814 (1) 134 doi:10.1007/s40278-020-81121-1
(2020) Dobutamine/epinephrine/terbutaline interaction. Reactions Weekly, 1814 (1) 135 doi:10.1007/s40278-020-81122-1
(2020) Docetaxel/fluorouracil/folinic-acid/oxaliplatin. Reactions Weekly, 1814 (1) 136 doi:10.1007/s40278-020-81123-1
(2020) Dolutegravir. Reactions Weekly, 1814 (1) 137 doi:10.1007/s40278-020-81124-1
(2020) Doxazosin/epinephrine. Reactions Weekly, 1814 (1) 138 doi:10.1007/s40278-020-81125-1
(2020) Doxorubicin/regorafenib. Reactions Weekly, 1814 (1) 139 doi:10.1007/s40278-020-81126-1
(2020) Doxycycline/hydroxychloroquine/sulfadiazine. Reactions Weekly, 1814 (1) 140 doi:10.1007/s40278-020-81127-1
(2020) Doxycycline/levofloxacin. Reactions Weekly, 1814 (1) 141 doi:10.1007/s40278-020-81128-1
(2020) Dupilumab. Reactions Weekly, 1814 (1) 142 doi:10.1007/s40278-020-81129-1
(2020) Durvalumab. Reactions Weekly, 1814 (1) 143 doi:10.1007/s40278-020-81130-0
(2020) Enasidenib. Reactions Weekly, 1814 (1) 144 doi:10.1007/s40278-020-81131-0
(2020) Enoxaparin sodium. Reactions Weekly, 1814 (1) 145 doi:10.1007/s40278-020-81132-0
(2020) Epidermal growth factor receptor antagonists/bevacizumab/crizotinib. Reactions Weekly, 1814 (1) 146 doi:10.1007/s40278-020-81133-0
(2020) Eptifibatide. Reactions Weekly, 1814 (1) 147 doi:10.1007/s40278-020-81134-0
(2020) Estradiol/progesterone. Reactions Weekly, 1814 (1) 148 doi:10.1007/s40278-020-81135-0
(2020) Fentanyl. Reactions Weekly, 1814 (1) 149 doi:10.1007/s40278-020-81136-0
(2020) Fludrocortisone. Reactions Weekly, 1814 (1) 150 doi:10.1007/s40278-020-81137-0
(2020) Fludrocortisone/furosemide/torasemide. Reactions Weekly, 1814 (1) 151 doi:10.1007/s40278-020-81138-0
(2020) Fluorouracil. Reactions Weekly, 1814 (1) 152 doi:10.1007/s40278-020-81139-0
(2020) Fluorouracil/folinic acid/irinotecan. Reactions Weekly, 1814 (1) 153 doi:10.1007/s40278-020-81140-z
(2020) Fluoxetine/metformin/sibutramine. Reactions Weekly, 1814 (1) 154 doi:10.1007/s40278-020-81141-z
(2020) Flupirtine. Reactions Weekly, 1814 (1) 155 doi:10.1007/s40278-020-81142-z
(2020) Fluvastatin/pravastatin. Reactions Weekly, 1814 (1) 156 doi:10.1007/s40278-020-81143-z
(2020) Fondaparinux sodium. Reactions Weekly, 1814 (1) 157 doi:10.1007/s40278-020-81144-z
(2020) Gefitinib/icotinib/osimertinib. Reactions Weekly, 1814 (1) 158 doi:10.1007/s40278-020-81145-z
(2020) Glatiramer-acetate. Reactions Weekly, 1814 (1) 159 doi:10.1007/s40278-020-81146-z
(2020) Grass pollen allergy immunotherapy. Reactions Weekly, 1814 (1) 160 doi:10.1007/s40278-020-81147-z
(2020) Heparin. Reactions Weekly, 1814 (1) 161 doi:10.1007/s40278-020-81148-z
(2020) Heparin. Reactions Weekly, 1814 (1) 162 doi:10.1007/s40278-020-81149-z
(2020) Heparin. Reactions Weekly, 1814 (1) 163 doi:10.1007/s40278-020-81150-y
(2020) Heparin/glycerol. Reactions Weekly, 1814 (1) 164 doi:10.1007/s40278-020-81151-y
(2020) Heparin/rituximab/steroids. Reactions Weekly, 1814 (1) 165 doi:10.1007/s40278-020-81152-y
(2020) Hydrochlorothiazide. Reactions Weekly, 1814 (1) 166 doi:10.1007/s40278-020-81153-y
(2020) Hydrochlorothiazide/triamterene/sodium valproate. Reactions Weekly, 1814 (1) 167 doi:10.1007/s40278-020-81154-y
(2020) Hydroxychloroquine. Reactions Weekly, 1814 (1) 168 doi:10.1007/s40278-020-81155-y
(2020) Hydroxychloroquine. Reactions Weekly, 1814 (1) 169 doi:10.1007/s40278-020-81156-y
(2020) Hydroxychloroquine. Reactions Weekly, 1814 (1) 170 doi:10.1007/s40278-020-81157-y
(2020) Hydroxychloroquine. Reactions Weekly, 1814 (1) 171 doi:10.1007/s40278-020-81158-y
(2020) Hydroxychloroquine/immunosuppressants. Reactions Weekly, 1814 (1) 172 doi:10.1007/s40278-020-81159-y
(2020) Ibrutinib/sorafenib. Reactions Weekly, 1814 (1) 173 doi:10.1007/s40278-020-81160-x
(2020) Imatinib. Reactions Weekly, 1814 (1) 174 doi:10.1007/s40278-020-81161-x
(2020) Immune globulin/rituximab/immunosuppressants. Reactions Weekly, 1814 (1) 175 doi:10.1007/s40278-020-81162-x
(2020) Immune-globulin. Reactions Weekly, 1814 (1) 176 doi:10.1007/s40278-020-81163-x
(2020) Immunosuppressants. Reactions Weekly, 1814 (1) 177 doi:10.1007/s40278-020-81164-x
(2020) Immunosuppressants. Reactions Weekly, 1814 (1) 178 doi:10.1007/s40278-020-81165-x
(2020) Immunosuppressants. Reactions Weekly, 1814 (1) 179 doi:10.1007/s40278-020-81166-x
(2020) Immunosuppressants. Reactions Weekly, 1814 (1) 180 doi:10.1007/s40278-020-81167-x
(2020) Immunosuppressants. Reactions Weekly, 1814 (1) 181 doi:10.1007/s40278-020-81168-x
(2020) Immunosuppressants. Reactions Weekly, 1814 (1) 182 doi:10.1007/s40278-020-81169-x
(2020) Immunosuppressants. Reactions Weekly, 1814 (1) 183 doi:10.1007/s40278-020-81170-9
(2020) Infliximab/prednisolone. Reactions Weekly, 1814 (1) 184 doi:10.1007/s40278-020-81171-9
(2020) Influenza-virus-vaccine/pneumococcal-13-valent-CRM197-vaccine-conjugate. Reactions Weekly, 1814 (1) 185 doi:10.1007/s40278-020-81172-9
(2020) Inotuzumab-ozogamicin/methotrexate/pegaspargase. Reactions Weekly, 1814 (1) 186 doi:10.1007/s40278-020-81173-9
(2020) Insulin overdose. Reactions Weekly, 1814 (1) 187 doi:10.1007/s40278-020-81174-9
(2020) Iohexol. Reactions Weekly, 1814 (1) 188 doi:10.1007/s40278-020-81175-9
(2020) Ipilimumab/nivolumab. Reactions Weekly, 1814 (1) 189 doi:10.1007/s40278-020-81176-9
(2020) Ipilimumab/nivolumab. Reactions Weekly, 1814 (1) 190 doi:10.1007/s40278-020-81177-9
(2020) Ipilimumab/nivolumab/pembrolizumab. Reactions Weekly, 1814 (1) 191 doi:10.1007/s40278-020-81178-9
(2020) Ipilimumab/nivolumab/pembrolizumab. Reactions Weekly, 1814 (1) 192 doi:10.1007/s40278-020-81179-9
(2020) Irinotecan. Reactions Weekly, 1814 (1) 193 doi:10.1007/s40278-020-81180-8
(2020) Iron. Reactions Weekly, 1814 (1) 194 doi:10.1007/s40278-020-81181-8
(2020) Isotretinoin. Reactions Weekly, 1814 (1) 195 doi:10.1007/s40278-020-81182-8
(2020) Isotretinoin. Reactions Weekly, 1814 (1) 196 doi:10.1007/s40278-020-81183-8
(2020) Ketamine. Reactions Weekly, 1814 (1) 197 doi:10.1007/s40278-020-81184-8
(2020) Ketamine abuse. Reactions Weekly, 1814 (1) 198 doi:10.1007/s40278-020-81185-8
(2020) Lamivudine. Reactions Weekly, 1814 (1) 199 doi:10.1007/s40278-020-81186-8
(2020) Lenalidomide/pomalidomide. Reactions Weekly, 1814 (1) 200 doi:10.1007/s40278-020-81187-8
(2020) Levamisole. Reactions Weekly, 1814 (1) 201 doi:10.1007/s40278-020-81188-8
(2020) Lidocaine. Reactions Weekly, 1814 (1) 202 doi:10.1007/s40278-020-81189-8
(2020) Linezolid. Reactions Weekly, 1814 (1) 203 doi:10.1007/s40278-020-81190-7
(2020) Linezolid. Reactions Weekly, 1814 (1) 204 doi:10.1007/s40278-020-81191-7
(2020) Lithium. Reactions Weekly, 1814 (1) 205 doi:10.1007/s40278-020-81192-7
(2020) Lithium. Reactions Weekly, 1814 (1) 206 doi:10.1007/s40278-020-81193-7
(2020) Lorazepam. Reactions Weekly, 1814 (1) 207 doi:10.1007/s40278-020-81194-7
(2020) Mercaptopurine. Reactions Weekly, 1814 (1) 208 doi:10.1007/s40278-020-81195-7
(2020) Meropenem/yttrium-90. Reactions Weekly, 1814 (1) 209 doi:10.1007/s40278-020-81196-7
(2020) Mesalazine/ustekinumab. Reactions Weekly, 1814 (1) 210 doi:10.1007/s40278-020-81197-7
(2020) Methotrexate. Reactions Weekly, 1814 (1) 211 doi:10.1007/s40278-020-81198-7
(2020) Methotrexate. Reactions Weekly, 1814 (1) 212 doi:10.1007/s40278-020-81199-7
(2020) Methotrexate/methylprednisolone/prednisolone. Reactions Weekly, 1814 (1) 213 doi:10.1007/s40278-020-81200-1
(2020) Methotrexate/misoprostol. Reactions Weekly, 1814 (1) 214 doi:10.1007/s40278-020-81201-1
(2020) Methotrexate/prednisolone/sulfasalazine. Reactions Weekly, 1814 (1) 215 doi:10.1007/s40278-020-81202-1
(2020) Methotrexate/tacrolimus. Reactions Weekly, 1814 (1) 216 doi:10.1007/s40278-020-81203-1
(2020) Methylprednisolone. Reactions Weekly, 1814 (1) 217 doi:10.1007/s40278-020-81204-1
(2020) Methylprednisolone/pembrolizumab interaction. Reactions Weekly, 1814 (1) 218 doi:10.1007/s40278-020-81205-1
(2020) Methylprednisolone/pirfenidone. Reactions Weekly, 1814 (1) 219 doi:10.1007/s40278-020-81206-1
(2020) Methylprednisolone/prednisolone. Reactions Weekly, 1814 (1) 220 doi:10.1007/s40278-020-81207-1
(2020) Metronidazole. Reactions Weekly, 1814 (1) 221 doi:10.1007/s40278-020-81208-1
(2020) Metronidazole. Reactions Weekly, 1814 (1) 222 doi:10.1007/s40278-020-81209-1
(2020) Metronidazole. Reactions Weekly, 1814 (1) 223 doi:10.1007/s40278-020-81210-0
(2020) Minocycline. Reactions Weekly, 1814 (1) 224 doi:10.1007/s40278-020-81211-0
(2020) Morphine. Reactions Weekly, 1814 (1) 225 doi:10.1007/s40278-020-81212-0
(2020) Morphine/oxytocin. Reactions Weekly, 1814 (1) 226 doi:10.1007/s40278-020-81213-0
(2020) Multiple drugs. Reactions Weekly, 1814 (1) 227 doi:10.1007/s40278-020-81214-0
(2020) Multiple drugs. Reactions Weekly, 1814 (1) 228 doi:10.1007/s40278-020-81215-0
(2020) Multiple drugs. Reactions Weekly, 1814 (1) 229 doi:10.1007/s40278-020-81216-0
(2020) Multiple drugs. Reactions Weekly, 1814 (1) 230 doi:10.1007/s40278-020-81217-0
(2020) Multiple drugs. Reactions Weekly, 1814 (1) 231 doi:10.1007/s40278-020-81218-0
(2020) Multiple drugs. Reactions Weekly, 1814 (1) 232 doi:10.1007/s40278-020-81219-0
(2020) Multiple drugs. Reactions Weekly, 1814 (1) 233 doi:10.1007/s40278-020-81220-z
(2020) Multiple drugs. Reactions Weekly, 1814 (1) 234 doi:10.1007/s40278-020-81221-z
(2020) Multiple drugs. Reactions Weekly, 1814 (1) 235 doi:10.1007/s40278-020-81222-z
(2020) Multiple drugs. Reactions Weekly, 1814 (1) 236 doi:10.1007/s40278-020-81223-z
(2020) Multiple drugs. Reactions Weekly, 1814 (1) 237 doi:10.1007/s40278-020-81224-z
(2020) Multiple drugs. Reactions Weekly, 1814 (1) 238 doi:10.1007/s40278-020-81225-z
(2020) Multiple drugs. Reactions Weekly, 1814 (1) 239 doi:10.1007/s40278-020-81226-z
(2020) Multiple drugs. Reactions Weekly, 1814 (1) 240 doi:10.1007/s40278-020-81227-z
(2020) Multiple drugs. Reactions Weekly, 1814 (1) 241 doi:10.1007/s40278-020-81228-z
(2020) Multiple drugs. Reactions Weekly, 1814 (1) 242 doi:10.1007/s40278-020-81229-z
(2020) Multiple drugs. Reactions Weekly, 1814 (1) 243 doi:10.1007/s40278-020-81230-y
(2020) Multiple drugs. Reactions Weekly, 1814 (1) 244 doi:10.1007/s40278-020-81231-y
(2020) Multiple drugs. Reactions Weekly, 1814 (1) 245 doi:10.1007/s40278-020-81232-y
(2020) Multiple drugs. Reactions Weekly, 1814 (1) 246 doi:10.1007/s40278-020-81233-y
(2020) Multiple drugs. Reactions Weekly, 1814 (1) 247 doi:10.1007/s40278-020-81234-y
(2020) Multiple drugs. Reactions Weekly, 1814 (1) 248 doi:10.1007/s40278-020-81235-y
(2020) Multiple drugs. Reactions Weekly, 1814 (1) 249 doi:10.1007/s40278-020-81236-y
(2020) Multiple drugs. Reactions Weekly, 1814 (1) 250 doi:10.1007/s40278-020-81237-y
1 2
Page 1 of 2		Next Page

See Also

These are possibly similar items as determined by title/reference text matching only.

(2020, July) Reactions Weekly Vol. 1811 (1) Springer Science and Business Media LLC
(2020, July) Reactions Weekly Vol. 1812 (1) Springer Science and Business Media LLC
(2020, July) Reactions Weekly Vol. 1813 (1) Springer Science and Business Media LLC
(2016, July) Reactions Weekly Vol. 1608 (1) Springer Science and Business Media LLC
(2016, July) Reactions Weekly Vol. 1609 (1) Springer Science and Business Media LLC
(2016, July) Reactions Weekly Vol. 1610 (1) Springer Science and Business Media LLC
(2016, July) Reactions Weekly Vol. 1611 (1) Springer Science and Business Media LLC
(2016, July) Reactions Weekly Vol. 1612 (1) Springer Science and Business Media LLC
(2003, July) Reactions Weekly Vol. 961 (1) Springer Science and Business Media LLC
(2007, July) Reactions Weekly Vol. 1162 (1) Springer Science and Business Media LLC
(2013, July) Reactions Weekly Vol. 1459 (1) Springer Science and Business Media LLC
 
and/or  
Mindat.org is an outreach project of the Hudson Institute of Mineralogy, a 501(c)(3) not-for-profit organization.
Copyright © mindat.org and the Hudson Institute of Mineralogy 1993-2025, except where stated. Most political location boundaries are © OpenStreetMap contributors. Mindat.org relies on the contributions of thousands of members and supporters. Founded in 2000 by Jolyon Ralph.
To cite: Ralph, J., Von Bargen, D., Martynov, P., Zhang, J., Que, X., Prabhu, A., Morrison, S. M., Li, W., Chen, W., & Ma, X. (2025). Mindat.org: The open access mineralogy database to accelerate data-intensive geoscience research. American Mineralogist, 110(6), 833–844. doi:10.2138/am-2024-9486.
Privacy Policy - Terms & Conditions - Contact Us / DMCA issues - Report a bug/vulnerability Current server date and time: August 22, 2025 16:46:52
Go to top of page